SCHEMBL337676

SCHEMBL337676

CCOC(=O)c1c(O)c2cc(-c3ccccc3)nnc2n(C)c1=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.58
KDM4E B2RXH2 6/20 0.58
TSHR P16473 1/20 0.49
RECQL P46063 1/20 0.49
LMNA P02545 5/20 0.47
GAA P10253 3/20 0.47
HPGD P15428 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
HTT P42858 1/20 0.46
MAPT P10636 4/20 0.45
HSD17B10 Q99714 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
MAPK10 P53779 1/20 0.44
NPC1 O15118 2/20 0.43
ALOX15 P16050 1/20 0.43
CCR6 P51684 1/20 0.43
RAB9A P51151 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2435689 0.87 ALDH1A1 (0.44) ALDH1A1KDM4ETSHRLMNAGAA
SCHEMBL10080871 0.82 ALDH1A1 (0.55) ALDH1A1KDM4ERECQLLMNAGAA
SCHEMBL2436105 0.81 EGLN1 (0.52) ALDH1A1KDM4ELMNAHPGDSMN1; SMN2
SCHEMBL336460 0.80 EGLN1 (0.55)
SCHEMBL10084718 0.78 MEN1 (0.45) KDM4ETSHRHTTMEN1KMT2A
SCHEMBL2578402 0.78 KDM4E (0.52) ALDH1A1KDM4ETSHRRECQLLMNA
SCHEMBL337343 0.77 KDM4E (0.51) ALDH1A1KDM4ETSHRRECQLLMNA
SCHEMBL11639617 0.76 ALDH1A1 (0.56) ALDH1A1KDM4ETSHRRECQLLMNA
SCHEMBL8137427 0.75 ALDH1A1 (0.65) ALDH1A1KDM4ERECQLLMNASMN1; SMN2
SCHEMBL8141322 0.74 ALDH1A1 (0.61) ALDH1A1KDM4ETSHRRECQLLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2142509-B1 QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE AMGEN INC (US) 2013-12-04 EP disclosed
US-8349868-B2 Azaquinolones that inhibit prolyl hydroxylase AMGEN INC. (US) 2013-01-08 US disclosed
US-8097620-B2 Diazaquinolones that inhibit prolyl hydroxylase activity AMGEN INC. (US) 2012-01-17 US disclosed
US-8048894-B2 Quinolones and azaquinolones that inhibit prolyl hydroxylase AMGEN INC. (US) 2011-11-01 US disclosed
US-20110224248-A1 AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE AMGEN INC. (US) 2011-09-15 US disclosed
EP-2155746-A2 DIAZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY Amgen, Inc (US) 2010-02-24 EP disclosed
EP-2142509-A2 QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE Amgen, Inc (US) 2010-01-13 EP disclosed
US-20090156605-A1 Quinolones and azaquinolones that inhbit prolyl hydroxylase AMGEN INC. (US) 2009-06-18 US disclosed
US-20090099171-A1 Diazaquinolones that inhibit prolyl hydroxylase activity AMGEN INC. (US) 2009-04-16 US disclosed
WO-2008137084-A2 DIAZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY AMGEN INC. (US) 2008-11-13 WO disclosed
WO-2008130600-A2 QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE AMGEN INC. (US) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099171-A1 Diazaquinolones that inhibit prolyl hydroxylase activity EGLN3, EGLN2, HIF1AN ALDH1A1 108/4885KDM4E 248/4885TSHR 3238/4885
US-20090156605-A1 Quinolones and azaquinolones that inhbit prolyl hydroxylase EGLN3, HIF1AN, EGLN2 ALDH1A1 191/4885KDM4E 336/4885TSHR 3302/4885
US-20110224248-A1 AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE HIF1AN, EGLN3, EGLN2 ALDH1A1 145/4885KDM4E 126/4885TSHR 3347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.